Tanovea is a drug owned by ELANCO US INC. It is protected by 4 US drug patents filed from 2025 to 2027. Out of these, 2 patents are active and 2 patents have expired. Details of Tanovea’s patents and their expiration are given below.
Exclusivity Information
Tanovea holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Tanovea's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Jul 15, 2026 |
About Tanovea
Tanovea is a drug
owned by ELANCO US INC.
Tanovea uses
Rabacfosadine as the active
ingredient.
Active Ingredient:
Tanovea uses
Rabacfosadine as the active ingredient.
Check out other Drugs and Companies using
Rabacfosadine ingredient.